Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.05.10.20097253: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Information extracted from included studies included title, year of publication, country, number of participants with each comorbidity who died and did not die, the RR/OR/HR of mortality of COVID-19 with each underlying condition, the mean or median age, proportion that was male, and other findings of interest. Table 2: Resources
Software and Algorithms Sentences Resources We performed a systematic literature search of PubMed (MEDLINE), OVID (MEDLINE, HEALTHSTAR), SCOPUS, and medrxiv.org, using search criteria provided in the supplemental material … SciScore for 10.1101/2020.05.10.20097253: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Information extracted from included studies included title, year of publication, country, number of participants with each comorbidity who died and did not die, the RR/OR/HR of mortality of COVID-19 with each underlying condition, the mean or median age, proportion that was male, and other findings of interest. Table 2: Resources
Software and Algorithms Sentences Resources We performed a systematic literature search of PubMed (MEDLINE), OVID (MEDLINE, HEALTHSTAR), SCOPUS, and medrxiv.org, using search criteria provided in the supplemental material (Supplemental Document 1). PubMedsuggested: (PubMed, RRID:SCR_004846)MEDLINEsuggested: (MEDLINE, RRID:SCR_002185)Our search criteria included the following keywords and MesH terms: (“COVID-19” OR “Coronavirus” or “SARS-CoV-2”) AND (“Mortality”) AND (“cardiovascular disease” OR “chronic obstructive pulmonary disease” OR “asthma” OR “Coronary heart disease” OR “hypertension” OR “T2D” or “DM” or “diabetes” OR “cancer” OR “chronic kidney disease” OR “chronic liver disease” OR “comorbidities” OR “chronic disease”, OR” “HIV/AIDS” OR” Human immunodeficiency virus infection and acquired immune deficiency syndrome”). MesHsuggested: (MeSH, RRID:SCR_004750)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and Limitations: As COVID-19 is still a relatively new phenomenon, there has been a limited number of comprehensive and conclusive studies related to mortality in diverse populations. Therefore, data from Africa and Australia were not included in this meta-analysis. We are hopeful that in the future, further research will be published that explores the association between COVID-19 mortality and preexisting chronic conditions in these regions. In addition to this, we were unable to explore the influence that cancer, HIV, and asthma may have on COVID-19 mortality. As mentioned above, further research is necessary to conclusively determine if individuals with these preexisting chronic conditions in these regions are at an increased risk for death from COVID-19. As previously mentioned, this meta-analysis employed a large number of studies, which allowed for a relatively large sample size (n=61,455). By doing this, we were able to explore a broad scope of chronic conditions, with over seven comorbidities included. This allows our meta-analysis to comprehensively cover a multitude of prevalent conditions throughout populations.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
-